Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Myriad Genetics is presenting six posters at the 2026 ASCO Annual Meeting, highlighting the prognostic power of its Precise MRD assay across diverse solid tumors. Interim data from the MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, shows 97% baseline detection and 16% ultrasensitive detection, with ctDNA positivity strongly correlating with recurrence risk.
Key figures
- Study patient count
- 1100
- Poster presentations
- 6
- Baseline detection rate
- 97%
- Ultrasensitive detection rate
- 16%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.